Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €12.00 EUR
Change Today +0.14 / 1.18%
Volume 29.7K
As of 9:11 AM 10/13/15 All times are local (Market data is delayed by at least 15 minutes).

ab science sa (AB) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/10/15 - €18.93
52 Week Low
10/16/14 - €7.16
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AB SCIENCE SA (AB)

Related News

No related news articles were found.

ab science sa (AB) Related Businessweek News

No Related Businessweek News Found

ab science sa (AB) Details

AB Science S.A., a pharmaceutical company, engages in the discovery, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicines. The company markets Masitinib for the treatment of oncology and inflammatory diseases for dogs and cats. It markets its Masitinib under the Masivet brand name in Europe; and Kinavet brand name in the United States. The company is also developing Masitinib in human indications that are in various Phase II and Phase III clinical trials for the treatment of oncology, inflammatory, hematology, and central nervous system diseases, as well as for the treatment of indolent systemic mastocytosis, non controlled severe asthma, refractory rheumatoid arthritis, progressive forms of multiple sclerosis, amyothrophic lateral sclerosis, and Alzheimer's diseases. It serves hospitals and specialist physicians. AB Science S.A. was founded in 2001 and is headquartered in Paris, France.

121 Employees
Last Reported Date: 04/30/15
Founded in 2001

ab science sa (AB) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: €227.7K
Compensation as of Fiscal Year 2014.

ab science sa (AB) Key Developments

AB Science SA Announces Cessation of its Rheumatoid Arthritis Study in Order to Focus on Clinical Studies with a Probability of Success Greater Than 50%

AB Science SA announced the decision to stop the phase 3 study of masitinib in rheumatoid arthritis in order to streamline its studies portfolio. This decision has been made following a futility test, conducted by the external Data and Safety Monitoring Board (DSMB), showing that the probability of success on the primary endpoint was below 50% for this study, including the resampling option. The futility test is based on the study's primary endpoint analysis without resampling and with a conditional power (predictive probability of success) of 20%. For this analysis it is considered that all the patients to be included in the study will follow the trend observed for patients already included at the time of the futility analysis. If the futility test is successful, the probability of success on the primary endpoint of the study may exceed 20%, without the resampling option. However, the study protocol includes also a resampling option (the possibility to increase the number of patients enrolled up to a factor two), which can be implemented if an efficacy trend is observed during the interim analysis that needs to be statistically demonstrated by increasing the number of patients in the study. Given the possibility of this option, the probability of success on the primary endpoint of the study can be estimated at 50%, by modifying the study sampling size if the futility test is successful. Alternatively, if the futility test fails, the probability of success on the primary endpoint of the study is below 50% with the resampling option. The company policy is to focus on indications with a predictive probability of success greater than 50% and a high medical need. The number of phase 3 studies initiated, which exceeds ten, makes possible this strategy to focus investments in the most promising indications. In addition, this strategy avoids incurring all the expenditures for a study with a probability of success deemed insufficient. As a reminder, mastocytosis, severe asthma, amyotrophic lateral sclerosis, progressive multiple sclerosis and Alzheimer's disease meet this dual condition since these diseases all represent unmet medical needs and since the masitinib phase 3 studies in these indications passed the futility test successfully.

AB Science SA Reports Consolidated Earnings Results for the First Half Ended June 30, 2015

AB Science SA reported consolidated earnings results for the first half ended June 30, 2015. For the period, the company's loss widened to EUR 13 million from EUR 7.2 million booked a year earlier due to increased research and development costs. Revenue was EUR 1,260,000 against 1,023,000 a year ago, up 23.2% on the year, mostly attributed to the marketing of a veterinary drug. The company booked an operating loss of EUR 12.4 million, compared with a loss of EUR 6.7 million a year ago. Net loss attributable to equity holders of the parent company was EUR 12,978,000 or EUR 0.39 per basic and diluted share against EUR 7,208,000 or EUR 0.22 per basic and diluted share a year ago. Net cash used in operating activities was EUR 13,059,000 against 6,405,000 a year ago. Acquisitions of fixed assets were EUR 291,000 against 362,000 a year ago.

AB Science S.A. - Special Call

To discuss the current positioning of masitinib in MS; to discuss the scientific rationale for developing masitinib in MS; to discuss the efficacy and safety update on the on-going phase 3 study; and to discuss the market potential for masitinib in MS


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AB:FP €12.00 EUR +0.14

AB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AB.
View Industry Companies

Industry Analysis


Industry Average

Valuation AB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 173.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 161.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AB SCIENCE SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at